Post-translational modifications in anaplastic thyroid carcinoma: biological mechanisms and therapeutic potential

Linkun Zhong1, Huizheng Li2, Jianhang Miao1

  • 1Department of General Surgery, Zhongshan City People's Hospital, Zhongshan, 528403, Guangdong Province, China.

PubMed

Insights

Post-translational modifications (PTMs) significantly impact anaplastic thyroid carcinoma (ATC) progression, influencing proliferation, metastasis, and treatment resistance. Understanding PTMs offers new therapeutic strategies and biomarkers for this lethal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Anaplastic thyroid carcinoma (ATC) is a highly lethal cancer with poor treatment outcomes.
  • Post-translational modifications (PTMs) regulate protein function and are critical in cancer development and progression.

Purpose of the Study:

  • To comprehensively review the role of PTMs in ATC progression.
  • To explore PTMs as potential biomarkers and therapeutic targets for ATC.

Main Methods:

  • Literature review focusing on PTMs (phosphorylation, ubiquitination, acetylation, glycosylation) in ATC.
  • Analysis of PTMs' impact on signaling pathways, proliferation, invasion, metastasis, and therapeutic resistance.

Main Results:

  • Dysregulated PTMs are key drivers of ATC progression, affecting proliferation, invasion, and metastasis.
  • Specific PTMs like phosphorylation and acetylation are implicated in targeted drug development and resistance.
  • Glycosylation is linked to dedifferentiation and presents novel therapeutic avenues.

Conclusions:

  • PTMs are crucial regulators of ATC biology and offer significant potential as biomarkers and therapeutic targets.
  • Further research into PTM interplay is needed to develop effective early intervention strategies for ATC patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K